Case No.: 56032US022

32692

Customer Number

Request for Continued Examination (RCE) Transmittal

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR § 1.8(a)]

M " 0' DOF	I hereby certify that this correspondence is being:
Mail Stop RCE Commissioner for Patents P.O. Box 1450	deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Alexandria, VA 22313-1450	□ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at 571-273-8300 or if filing with a Petition to Withdraw from Issue to: 571-273-0025.
	★ Transmitted to United States Patent and Trademark Office on the date shown below via the Office electronic filing system.
	July 16, 2009 /Chris Johnson/
	Date Signed by: Chris Johnson
First Named Inventor:	Cantor, Adam S.
Application No. :	09/965610 Confirmation No.: 8132
Filed:	September 26, 2001
Title:	COMPOSITION FOR THE TRANSDERMAL DELIVERY OF FENTANYL
This is a Request for Continued	Examination (RCE) under 37 CFR § 1.114 of the above-identified application.
amendments enclosed with the	7 CFR § 1.114 Note: If the RCE is proper, any previously filed unentered amendments and RCE will be entered in the order in which they were filed unless Applicant instructs otherwise. If e any previously filed unentered amendment(s) entered, Applicant must request non-entry of such
a. Previously submit be considered as i. Consider the ii. Other: b. Enclosed: i. Amendr ii. Affidavir	ted. If a final Office Action is outstanding, any amendments filed after the final Office Action may a submission even if this box is not checked. arguments in the Appeal Brief or Reply Brief previously filed on ment/Reply c(s)/Declaration(s) tion Disclosure Statement (IDS)/Supplemental IDS
	the above-identified application is requested under 37 CFR 1.103(c) for a period of bension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
 3. Fees: The RCE fee (\$810.00) under 37 CFR § 1.17(e) is required by 37 CFR § 1.114 when the RCE is filed. The RCE fee required under 37 CFR § 1.17(e) will be made at the time of submission via EFS-Web. In the event fees are not or cannot be paid at the time of EFS-Web submission, please charge any fees under 37 CFR § 1.17 which may be required to Deposit Account No. 13-3723. The Director is authorized to charge the RCE fee required by 37 CFR § 1.17(e) to Deposit Account No. 13-3723. Please charge any additional fees associated with the prosecution of this application to Deposit Account No. 13-3723. This authorization includes the fee for any necessary extension of time under 37 CFR § 1.136(a). To the extent any such extension should become necessary, it is hereby requested. Please credit any overpayment to the same deposit account. 	
4. A Request for Extension of Time is being filed concurrently.	
	Respectfully submitted,
<u>July 16, 2009</u> Date	By: <u>/Robert W. Sprague/</u> Robert W. Sprague, Reg. No.: 30,497 Telephone No.: 651-733-4247
Office of Intellectual Property Coun 3M Innovative Properties Company Facsimile No.: (651) 736-3833	sel